Reaction

Breast Cancer Recurrent reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,111 reports · 56 co-occurring drugs

As of the last recalculation, Breast Cancer Recurrent appears in 3,111 FAERS reports alongside 56 co-occurring drug terms. The strongest observed disproportionality signal is ANASTROZOLE (PRR 76.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Anastrozole	370	76.4	77.2
Fulvestrant	305	68.4	69.0
Anastrozole Tablets	190	63.0	63.6
Exemestane	175	57.9	58.3
Letrozole	429	53.9	54.3
Ribociclib	234	53.6	54.0
Ado-Trastuzumab Emtansine	65	52.7	53.1
Letrozole Tablets	269	40.9	41.1
Trastuzumab	363	39.9	40.1
Pertuzumab	138	35.5	35.7
Conjugated Estrogens And Medroxyprogesterone Acetate	99	29.0	29.1
Goserelin	50	25.3	25.4
Conjugated Estrogens	151	18.2	18.2
Docetaxel Anhydrous	173	18.1	18.2
Docetaxel	173	18.1	18.2
Estrogens, Conjugated	151	17.8	17.9
Lapatinib	40	17.5	17.5
Medroxyprogesterone Acetate	120	16.7	16.8
Rocuronium Bromide	29	16.6	16.7
Paclitaxel (Aibumin-Bound)	171	14.7	14.7
Zoledronic Acid	85	14.5	14.6
Capecitabine	187	14.5	14.5
Paclitaxel	195	14.0	14.0
Everolimus	95	12.9	12.9
Everolimus Tablets	31	12.5	12.5
Palbociclib	160	11.8	11.8
Raloxifene Hydrochloride	24	11.1	11.1
Olaparib	28	9.0	9.0
Cyclophosphamide Injection, Solution	217	8.7	8.8
Cyclophosphamide	217	8.7	8.8
Cyclophosphamide For Injection	217	8.7	8.8
Doxorubicin	110	8.5	8.5
Gemcitabine Hydrochloride	52	6.7	6.7
Abemaciclib	19	6.4	6.4
Baricitinib	9	6.3	6.3
Gemcitabine	35	6.0	6.0
Carboplatin	107	5.8	5.8
Telmisartan	15	5.6	5.6
Fluorouracil Cream, 0.5%	59	5.3	5.3
Fluorouracil	59	5.2	5.2
Filgrastim	28	5.0	5.0
Doxorubicin Hydrochloride	22	4.5	4.5
Amlodipine Besylate And Benazepril Hydrochloride	6	4.4	4.4
Quinapril Hydrochloride	5	4.2	4.2
Denosumab	113	3.8	3.8
Fam-Trastuzumab Deruxtecan-Nxki	5	3.3	3.3
Teduglutide	6	3.0	3.0
Bevacizumab	53	2.9	2.9
Interferon Beta-1A	82	2.9	2.9
Pembrolizumab	45	2.9	2.9
Diroximel Fumarate	5	2.8	2.8
Pegfilgrastim	38	2.6	2.6
Inclisiran	3	2.5	2.5
Alpelisib	3	2.3	2.3
Peginterferon Beta-1A	4	2.0	2.0
Benralizumab	5	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.